Skip to content
10-Q

Quarterly Report

Intra-Cellular Therapies, Inc.

0001628280-24-020849

← back to feed
Filed
May 7, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 3, 2024 105.57M sh
Shares Diluted Q1 2024 · Mar 31, 2024 96.88M sh
Shares Diluted Q1 2024 · Mar 31, 2023 95.13M sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$34.12M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$60.07M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $139.82M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $147.77M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $75.73M
Stockholders Equity Q1 2024 · Mar 31, 2024 $599.5M
Stockholders Equity Q1 2024 · Dec 31, 2023 $591.42M
Stockholders Equity Q1 2024 · Mar 31, 2023 $627.61M
Stockholders Equity Q1 2024 · Dec 31, 2022 $656.07M
Current Liabilities Q1 2024 · Mar 31, 2024 $134.8M
Current Liabilities Q1 2024 · Dec 31, 2023 $123.55M
Total Liabilities Q1 2024 · Mar 31, 2024 $147.54M
Total Liabilities Q1 2024 · Dec 31, 2023 $136.87M
Current Assets Q1 2024 · Mar 31, 2024 $690.53M
Current Assets Q1 2024 · Dec 31, 2023 $667.8M
Total Assets Q1 2024 · Mar 31, 2024 $747.04M
Total Assets Q1 2024 · Dec 31, 2023 $728.3M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.16
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.46
Eps Basic Q1 2024 · Mar 31, 2024 −$0.16
Eps Basic Q1 2024 · Mar 31, 2023 −$0.46
Rd Expense Q1 2024 · Mar 31, 2024 $42.83M
Rd Expense Q1 2024 · Mar 31, 2023 $38.02M
Net Income Q1 2024 · Mar 31, 2024 −$15.25M
Net Income Q1 2024 · Mar 31, 2023 −$44.05M
Operating Income Q1 2024 · Mar 31, 2024 −$20.95M
Operating Income Q1 2024 · Mar 31, 2023 −$48.39M
Revenue Q1 2024 · Mar 31, 2024 $144.87M
Revenue Q1 2024 · Mar 31, 2023 $95.31M